SPOTLIGHT: Helicos cuts IPO price


Helicos BioSciences has cut its IPO price for the second time. The company cut the price per share to $9 after originally citing a range of $13 to $15 a share. The company plans to launch the HeliScope system for genetic analysis in the fourth quarter. Report

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.